Menu
1 min read · estimated
APPROVED USE
What FDA approved
Patients age 12 and older with locally advanced or metastatic differentiated thyroid cancer that progressed after a VEGFR-directed therapy, when radioactive iodine is ineffective or inappropriate.
LAMPGEN ANALYSIS
Why it matters
The decision adds a later-line option for differentiated thyroid cancer after VEGFR inhibition.
What research teams should watch
Check age, thyroid histology, progression on prior treatment and the radioactive iodine history.
PRIMARY RECORDS